Optimized Costoclavicular Block for Elderly Proximal Humeral Fracture Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorShanghai Tong Ren Hospital

About this trial

Background: Proximal humeral fractures are common in elderly patients and often require surgical fixation (open reduction and internal fixation). Traditional regional anesthesia techniques, such as the interscalene brachial plexus block, may provide incomplete pain relief in the medial upper arm area and carry a high risk of hemidiaphragmatic paralysis, which can lead to breathing difficulties.

Objective: This study aims to evaluate whether an optimized nerve block strategy-ultrasound-guided costoclavicular brachial plexus block combined with superficial cervical plexus block and T2 thoracic paravertebral block-improves anesthetic success and reduces diaphragm dysfunction compared to the traditional interscalene approach in elderly patients undergoing proximal humeral fracture surgery.

Study Design: This is a multicenter, prospective, randomized, controlled, double-blind (participants and outcome assessors), superiority clinical trial.

Population: A total of 356 elderly patients (aged ≥65 years) with unilateral proximal humeral fractures scheduled for open reduction and internal fixation via an anterior surgical approach will be enrolled from three centers in Shanghai, China.

Intervention: Participants will be randomly assigned in a 1:1 ratio to one of two groups:

* Experimental Group (Optimized Strategy): Receives ultrasound-guided costoclavicular brachial plexus block + superficial cervical plexus block + T2 thoracic paravertebral block (0.375% ropivacaine 20 mL for brachial plexus, 0.25% ropivacaine 10 mL for each of the other blocks). * Control Group (Traditional Strategy): Receives ultrasound-guided interscalene brachial plexus block + superficial cervical plexus block + T2 thoracic paravertebral block (same drug regimen).

All nerve blocks will be performed under ultrasound guidance by a single anesthesiologist. Patients and outcome assessors will be blinded to group assignment; the performing anesthesiologist cannot be blinded due to the distinct anatomical approaches.

Main Outcomes:

* Primary Outcome: Nerve block success rate, defined as no pain or only mild pain requiring no rescue analgesics (e.g., intravenous opioids, conversion to general anesthesia, or local infiltration) during surgery. * Key Secondary Outcomes: Rate of hemidiaphragmatic paralysis (assessed by ultrasound M-mode); rate of conversion to general anesthesia; postoperative pain (NRS, 0-10) at 24 hours; perioperative stress biomarkers (cortisol, ACTH, IL-6, HMGB-1, CRP, galectin-3); and postoperative shoulder function recovery.

Safety Monitoring: Adverse events, including unplanned conversion to general anesthesia, respiratory depression, pneumothorax, and severe hemidiaphragmatic paralysis, will be recorded and managed according to predefined protocols. An independent Data Monitoring Committee will review safety data and conduct interim analyses for futility.

Study Duration: The study is expected to take approximately 24 months from first patient enrollment to final follow-up completion.

Ethical Approval: This study has been approved by the Ethics Committee of Shanghai Tongren Hospital. Approvals from the ethics committees of the other participating centers (Shanghai Sixth People's Hospital and Shanghai Xuhui Central Hospital) will be obtained before study initiation at those sites.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Age ≥65 years

BMI <30

American Society of Anesthesiologists (ASA) physical status I to III

Disqualifiers

Inability to perform T2 thoracic paravertebral block for any reason

Coagulation dysfunction or current use of anticoagulant therapy

History of upper extremity nerve injury or phrenic nerve injury

Severe polytrauma

Trial design

Design model

Parallel

Treatments tested in this trial

  • Costoclavicular Brachial Plexus Block

    Procedure/Surgery

    Ultrasound-guided brachial plexus block performed at the costoclavicular space. The patient is placed in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe is used to identify the brachial plexus at the costoclavicular space. Using an in-plane technique, 0.375% ropivacaine 20 mL is injected. This intervention is administered once prior to surgery.

  • Interscalene Brachial Plexus Block

    Procedure/Surgery

    Ultrasound-guided brachial plexus block performed at the interscalene groove. The patient is placed in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe is used to identify the brachial plexus between the anterior and middle scalene muscles. Using an in-plane technique, 0.375% ropivacaine 20 mL is injected. This intervention is administered once prior to surgery.

  • Superficial Cervical Plexus Block

    Procedure/Surgery

    Ultrasound-guided superficial cervical plexus block. The patient is placed in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe is used to identify the superficial cervical plexus at the lateral border of the sternocleidomastoid muscle. Using an in-plane technique, 0.25% ropivacaine 10 mL is injected. This intervention is administered once prior to surgery.

  • T2 Thoracic Paravertebral Block

    Procedure/Surgery

    Ultrasound-guided T2 thoracic paravertebral block. The patient is placed in the lateral decubitus position with the operative side up. A low-frequency ultrasound probe is used to identify the T2 transverse process, rib, pleura, and costotransverse ligament. Using an in-plane technique, 0.25% ropivacaine 10 mL is injected. This intervention is administered once prior to surgery.

Treatment groups

356 Participants
are divided into 2 treatment groups
Group A: Costoclavicular Block GroupExperimental treatment 3 interventions
Group B: Interscalene Block GroupActive comparator 3 interventions

Trial outcomes

Primary outcomes

1

Nerve Block Success Rate

Nerve block success is defined as no pain or only mild pain during surgery, with no need for rescue analgesics (including intravenous opioids, conversion to general anesthesia, or local infiltration). Block failure is defined as significant pain requiring any rescue analgesic measure to complete the surgery.

Time frame
Intraoperative (assessed immediately after surgical incision and throughout the procedure)

Secondary outcomes

1

Sensory Block in Four Regions

Sensory block is assessed using pinprick test at 20 minutes after nerve block completion in four regions: distal clavicular region, deltoid region, medial upper arm region, and lateral upper arm region. Grading: 0=no block (sharp pain), 1=partial block (reduced pain sensation), 2=complete block (no pain sensation).

Time frame
20 minutes after nerve block completion
2

Vasoactive Medication Requirements

Total intraoperative doses of vasoactive medications including urapidil, ephedrine, phenylephrine, and atropine.

Time frame
Intraoperative
3

Rate of Hemidiaphragmatic Paralysis

Hemidiaphragmatic paralysis is assessed by ultrasound M-mode (sniff test). Complete paralysis: diaphragm excursion reduced by ≥75% from baseline or paradoxical movement. Partial paralysis: reduction of 25%-75%. No paralysis: reduction \<25%.

Time frame
35 minutes after nerve block completion
4

Proportion of Surgeries Completed with Remifentanil Assistance

Proportion of patients who require intravenous remifentanil (0.25 μg/kg/min) to tolerate the surgery without conversion to general anesthesia.

Time frame
Intraoperative

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shanghai Tong Ren Hospital

Lead sponsor

Shanghai 6th People's Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: